SKELETAL MUSCLE RELAXANTS

Dr. Yousef Al-saraireh Associate Professor Faculty of Medicine

DEFINITION


Skeletal muscle relaxants are drugs that act peripherally at neuromuscular junction/ muscle fiber itself or centrally in the cerebrospinal axis to reduce muscle tone and /or cause paralysis.

- Drugs that affect skeletal muscle function fall into two major groups:
 - 1. Neuromuscular blocking drugs
 - 2. Spasmolytics

Neuromuscular Junction

- With the arrival of an <u>action potential</u> at <u>motor nerve terminal</u>, influx of Ca, and release of <u>acetylcholine (ACh)</u>
- <u>ACh</u> diffuses across synaptic cleft to <u>nicotinic</u> <u>receptor</u> located on the <u>motor end plate</u>
- Combination of Ach with receptor causes opening of <u>Na and K channels</u>
- Na moves inside producing <u>depolarisation</u> of <u>motor end plate membrane</u>
- <u>Muscle contraction</u> is then initiated by <u>excitation-contraction coupling</u>

The Neuromuscular Junction



• The released Ach is quickly removed by enzymatic destruction by <u>acetylcholinesterase</u> (splits Ach into choline and acetate), and thereby <u>terminates action</u> <u>of Ach</u>


- <u>Skeletal muscle relaxation and paralysis</u> occur from interruption of function at several sites including:
 - <u>The motor end plate</u>
 - <u>Central nervous system</u>
 - <u>Contractile apparatus</u>

1. Neuromuscular blocking drugs

- <u>Cite of action</u>: interfere with cholinergic transmission at neuromuscular end plate
- All of **neuromuscular blocking drugs** are <u>highly polar</u> & <u>inactive when administered</u> <u>by mouth</u>
- They are always administered <u>intravenously</u> (i.v.)

Therapeutic uses

- **1. To provide muscle relaxation** <u>**during surgery**</u> (adjuvant to anesthesia)
- 2.They relax <u>vocal cords</u> & facilitate <u>tracheal intubation</u>
- 3. Intensive care units (ICU)
 - Because neuromuscular block <u>may</u> <u>paralyse muscles required for</u> <u>breathing</u>, <u>mechanical</u> <u>ventilation</u> should be available



Neuromuscular blocking drugs

<u>A. Competitive (non-depolarising blocking</u> <u>drugs):</u>

- Constitute the majority of clinically-relevant neuromuscular blockers
- These drugs are <u>competitive antagonists of</u> <u>Ach</u>

- They bind to nicotinic receptors, <u>prevent</u> <u>access of Ach to its receptors</u> & <u>prevent</u> <u>depolarisation</u>, the result is <u>flaccid paralysis</u>

A. Competitive (non-depolarising blocking drugs):

- Two major families of competitive antagonists: 1. Isoquinoline derivatives:
- Atracurium
- Tubocurarine
- Cisatracurium
- Mivacurium

2. Steroid derivatives

- Pancuronium
- Vecuronium
- Pipecuronium
- Rocuronium

• Non-depolarising blocking drug is chosen according to its:

- 1. <u>Onset of effect</u>
- 2. Duration of action:
 - Short-acting (15-30 min), mivacurium
 - Intermediate-acting (30-40 min),
 - atracurium
 - Long-acting (60-120 min), pancuronium
- 3. Side-effects
- -Isoquinoline derivatives (except cisatracurium) are associated with <u>histamine release</u> which can cause flushing, hypotension, tachycardia & bronchospasm
- <u>-Steroid muscle relaxants</u> are not associated with histamine release
- -Non-depolarising muscle relaxants <u>have a slower onset</u> <u>of action</u> than suxamethonium

1. Atracurium:

- Short to intermediate duration of action
- It undergoes **non-enzymatic metabolism** which is **independent of liver & kidney function**
- Thus it is used **in patients with hepatic or renal impairment**

2. Pancuronium

- Has a long duration of action
- Is often used in patients receiving long-term mechanical ventilation in intensive care units

Reversal of non-depolarising blocking drugs

• Reversal of this type can be achieved with <u>cholinesterase inhibitor</u> drugs, such as <u>neostigmine</u>

• <u>Prevents destruction of Ach by</u> <u>cholinestarase</u>, allowing accumulation of Ach at nerve endings & reduce competitive effect blocking agents

• Neostigmine is given **intravenously**

• It acts in <u>4 minutes</u> & lasts for <u>30 minutes</u>

B. DEPOLARISING BLOCKING DRUGS:

- **Succinylcholine (Suxamethonium)** is the only drug used clinically
- Act by depolarising the end plate, similar to Ach, except that it produces a longer effect

Mechanism of action

o <u>Phase I (depolarising phase):</u>

- <u>Suxamethonium</u> reacts with nicotinic receptor & causes <u>depolarisation</u> of end plate

- This in turn **spreads & depolarises adjacent membranes**, causing **generalised disorganised contractions** of muscle motor units (transient <u>muscle fasciculations</u>) -Because Suxamethonium <u>is not metabolised effectively at</u> <u>the synapse</u>

-The membrane <u>remains depolarised & unresponsive to</u> <u>additional impulses</u>

• <u>Phase II (desensitising phase):</u>

- -With continued exposure to Suxamethonium, initial end plate depolarisation decreases & membrane becomes repolarised
 - Despite this repolarisation, membrane cannot easily be depolarised again (it is desensitised), this causes flaccid paralysis
- <u>Suxamethonium</u> has:
 - Most rapid onset (<u>30 seconds</u>)
 - Shortest duration of action (5-10 minutes)

- <u>Tracheal intubation</u> is possible in <u>less than 60</u> <u>seconds</u> & total paralysis lasts up to <u>4 minutes</u>
- <u>Suxamethonium</u> is destroyed by plasma cholinesterase
- Repeated injections of <u>Suxamethonium</u> can cause **bradycardia & ventricular arrest** due to <u>activation of cholinoreceptors</u> in heart & can be prevented by <u>atropine</u>

Side effects:

1. Hyperkalemia:

- Suxamethonium depolarisation causes a release of K from muscle
- This a problem only if patient's plasma K is already high, e.g. acute renal failure
- In patients with spinal cord injuries & those with major burns, suxamethonium may cause a release of K, sufficient to cause cardiac arrest

2. Muscle pain:

- Is an important **<u>postoperative complaint</u>** in patients who have received succinylcholine -This is due <u>to secondary damage produced in</u> <u>muscle by unsynchronised contractions of</u> <u>adjacent muscle fibers</u> just before paralysis

<u>-Suxamethonium</u> should be given after anesthesia because paralysis is usually preceded by <u>painful</u> <u>muscle fasciculation</u>

<u>3. Apnea:</u>

-in patients who are deficients to plasma cholinesterse

2. Spasmolytics

- <u>Spasticity</u> is <u>disorder of motor system especially</u> <u>CNS</u>, certain muscles are <u>continuously contracted</u>
- It is associated with a variety of neurologic conditions: <u>cerebral palsy, multiple sclerosis &</u> <u>stroke</u>
- Spasmolytics are called <u>centrally acting</u> <u>muscle relaxants</u>
- Spasmolytics are used to reduce spasticity by:
- Either <u>enhancing level of inhibition</u> or <u>reducing</u> <u>level of excitation</u> that motor neuron receives
- Interfering directly with <u>skeletal muscle</u> <u>excitation</u>-<u>contraction coupling</u>

1. Diazepam:

 Benzodiazepines facilitate action of γaminobutyric acid (GABA) in CNS

- It acts at all $\ensuremath{\mathsf{GABA}}_A\,\ensuremath{\mathsf{synapses}}$
- It can be used in patients with muscle spasm of any origin, including local muscle trauma
 - It produces sedation in most patients at doses required to reduce muscle tone

2.Baclofen:

- It acts as GABA agonist at GABA_B receptors
- -Activation of receptors in brain by baclofen results in hyperpolarisation
- -This hyperpolarisation serve a presynaptic inhibitory function, by reducing Ca influx, to reduce release of excitatory neurotransmittors in both brain & spinal cord

Baclofen is at least as effective as diazepam in reducing spasticity & causes much less sedation

It dose not reduce general muscle strength as much as dantrolene

Rapidly & completely absorbed after oral use half-life of 3-4 hours

Dosage 15 mg twice daily, increasing to 100 mg daily

3. Dantrolene:

- It reduces skeletal muscle strength by
- interfering with excitation-contraction coupling in muscle fiber
 - The normal contractile response involves
- <u>release of Ca from its stores in sarcoplasmic</u> <u>reticulum</u>
- -Ryanodine receptor mediates release of Ca
- Ca brings interaction of <u>actin with myosin &</u> <u>initiates muscle contraction</u>

<u>Cite of action:</u>

- Binds to ryanodine receptor & decreasing intracellular Ca concentration
- half-life is <u>8 hours</u>
- Treatment begun with <u>25 mg daily</u>, increasing to <u>100 mg four times daily</u>
- Major adverse effects are **generalised muscle weakness & sedation**

4. Tizanidine:

- Is a newly introduced <u>alpha₂-adrenocptor</u> <u>agonist</u>
- It is indicated for spasticity associated with <u>multiple sclerosis or spinal cord</u> <u>injury</u>

Drugs used for acute local muscle spasm

Orphenadrine, metaxalone, cyclobenzabine

-They relieve <u>acute temporary muscle spasm</u> <u>caused by trauma or strain</u>

- Most act as sedative at level of <u>spinal cord or</u> <u>brain stem</u>